Molina Healthcare is a publicly traded company in the Healthcare sector. This company operates across Healthcare and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 22 active Congressional signals mentioning Molina Healthcare, including 20 bills and 2 federal contracts. The current legislative sentiment is predominantly bullish, suggesting potential tailwinds from government policy.
HR8375, the Medicare Advantage Improvement Act of 2026, introduces a 72-hour deadline for prior authorization decisions effective January 2028. The bill is in early legislative stage (sponsor introductory remarks only, April 2026). MA insurers face compliance costs, but the multi-year timeline reduces near-term market disruption. Major MA-exposed insurers like UNH and HUM face the highest absolute operational burden; HUM is most exposed relative to market cap. Real market data shows MA-insurer stocks rallied 15-60% over the last 30 days prior to this bill's introduction, indicating the bill is a manageable headwind rather than a sector-reshaping event at this stage.
This $23.2 million Department of Veterans Affairs contract for Veteran Experience Services is awarded to a private entity, but signifies continued federal investment in veteran healthcare services. Publicly traded healthcare providers and technology companies supporting federal health initiatives could see indirect benefits from this sustained focus.
HR8201 is a procedural early-stage bill authorizing $3.5B over five years to mandate behavioral health services at community health centers. Near-zero probability of passage this Congress. No immediate market impact for any sector. The bill is purely informational at this stage.
This $724M contract award to Optum Public Sector Solutions, a subsidiary of UnitedHealth Group, for the Department of Veterans Affairs, represents a significant revenue stream for the company and is supported by ongoing legislative efforts to strengthen healthcare workforce programs. The award reinforces UnitedHealth Group's dominant position in federal healthcare IT and services, with potential positive implications for its stock performance.
The ANCHOR Act of 2025 creates a state option to expand Medicaid to uninsured adults with serious mental illness or substance use disorder at or below 100% FPL. The bill is early-stage (referred to House Energy & Commerce) but has a Senate companion and regulatory tailwinds from an April 2026 executive order. Pure-play Medicaid managed care insurers Centene ($CNC) and Molina ($MOH) are structural beneficiaries, though no funding is authorized until states adopt and federal appropriations follow.
The ANCHOR Act of 2025 (S. 3300) creates a new state option to expand Medicaid eligibility to uninsured adults with serious mental illness or substance use disorder at or below 100% FPL. The bill is in early legislative stages—referred to Senate Finance Committee December 2025. Despite early status, the market is pricing in passage: CNC has rallied +62% in 30 days to $53.11, MOH +46% to $195.22, and HUM +39% to $241.35. Centene, Molina, and Humana are the primary structural beneficiaries due to their outsized Medicaid MCO exposure.
The Medicaid Primary Care Improvement Act (S.3298) is a procedural, early-stage bill that clarifies states may use direct primary care arrangements in Medicaid but authorizes zero funding and mandates only guidance and a report. Near-term market impact on Medicaid MCOs is neutral. Recent 30-day rallies in MOH (+46%) and CNC (+62%) are driven by factors unrelated to this stalled legislation.
HR6479 is an early-stage bill with no near-term path to enactment. Recent managed care stock rallies are tied to general sector optimism, not this specific legislation. No actionable trading signal from this bill at this point.
H.J.Res.123 would nullify a CMS rule that tightened Marketplace enrollment integrity. The bill is early stage (referred to committee) but has a failed companion in the Senate. Market pricing in $CNC and $MOH has been extremely bullish (+63% and +46% over 30 days) based on broader momentum, not this legislative risk. If the resolution gains traction, it creates downside risk for pure-play ACA insurers.
The ACO Assignment Improvement Act of 2025 widens Medicare Shared Savings Program attribution to include NP and PA visits. This directly benefits ACO operators among major Medicare Advantage insurers (UNH, HUM, CVS, CNC, MOH) by expanding their addressable patient pool for shared savings without additional provider recruitment. The bill is at early legislative stage with a bipartisan Senate sponsorship, but the mechanism is structurally favorable for the sector.
The Ensuring Excellence in Mental Health Act expands Medicare and Medicaid coverage for Certified Community Behavioral Health Clinics (CCBHCs), creating a new revenue stream for managed care organizations via established prospective payment systems. The bill is in early committee stage with three cosponsors and bipartisan support, but actual appropriations are separate. Real market data shows UNH, CNC, and MOH have seen massive recent rallies — CNC up 28% in 7 days and 63.5% in 30 days, MOH up 10.89% in 7 days, UNH up 36.12% in 30 days — indicating the market is already pricing in tailwinds from this and related behavioral health policy moves.
S.1847 is an early-stage bill expanding self-funded association health plans for small businesses, structurally negative for fully insured commercial carriers. The bill has no dollar authorization and remains in committee with only 6 sponsors — near-term passage probability is low. Real market data shows large health insurers (UNH, HUM, CVS, CNC) surging 15-55% in the last 30 days, but this rally is unrelated to S.1847 and driven by broader sector dynamics.
HR6512, the Putting Patients First Healthcare Freedom Act, is an early-stage bill that would eliminate enhanced ACA premium subsidies, directly threatening $5-9 billion in annual premium revenue for UnitedHealth, Humana, Centene, and Molina. The bill has only 3 sponsors and 4 committee referrals, making passage unlikely in its current form, but the structural risk to the managed care sector is clearly defined. Despite the legislative risk, actual market data shows all four tickers surging over the past 30 days ($CNC +64%, $MOH +47%, $HUM +40%, $UNH +36%), indicating the market is pricing in a 'do nothing' outcome for this specific legislation.
The Medicare Advantage Prompt Pay Act (HR5454) is early-stage legislation that would mandate MA plans to pay 95% of clean claims within 14 days (electronic in-network) or 30 days (other). This eliminates float income and increases administrative costs for MA insurers. Recent rallies in UNH (+3.3% 7-day), HUM (+12.12%), ELV (+8.12%), MOH (+10.8%), and CVS (+6.9%) appear disconnected from this structural headwind.
HR6178, introduced in November 2025 and referred to two committees, mandates no-cost lung cancer screenings and expanded tobacco cessation services under Medicaid, Medicare, and private insurance. This creates a direct revenue tailwind for diagnostic lab companies $LH and $DGX through increased test volume, and a pharmacy/PBM benefit for $CVS through mandated tobacco cessation drug coverage. Health insurers ($UNH, $HUM, $CNC, $MOH) face a neutral cost burden from the coverage mandate and prior authorization ban, with manageable MLR impact given the preventive nature of the service. The bill is early-stage with no appropriation attached.
The I CAN Act (HR1317) structurally lowers healthcare labor costs by expanding APRN scope under Medicare/Medicaid, directly benefiting managed care insurers. Real market data confirms managed-care insurers $CNC (+27.93% 7-day, +63.41% 30-day), $MOH (+10.81% 7-day, +46.26% 30-day), and $HUM (+12.05% 7-day, +39.09% 30-day) are already pricing in this regulatory tailwind. The bill is early-stage but has a companion in the Senate and executive-order tailwinds — pure-play Medicaid/Medicare insurers are the structural winners.
The Veterans' ACCESS Act (HR740) mandates VA referrals to private providers for eligible veterans, structurally diverting patient volume from VA facilities to commercial managed care organizations. The bill is authorization-only with no direct appropriations, but the policy mandate alone is a clear, multi-billion-dollar revenue driver for $UNH, $HUM, $MOH, $CI, and $CVS. Real market data shows these stocks already pricing in passage: 30-day gains of +34.5% ($UNH), +39.6% ($HUM), +44.6% ($MOH), +7.3% ($CI), and +15.4% ($CVS) since late March 2026.
HR 2048 eliminates the 29-month cumulative waiting period for SSDI and Medicare for metastatic breast cancer patients. The bill is in early legislative stages (referred to Ways and Means), but the identical Senate companion (S3442) increases passage odds. Major health insurers ($UNH, $HUM, $CVS, $CI, $MOH, $CNC) would benefit from accelerated Medicare enrollment, bringing forward premium revenue. Over the past 7 days these tickers have rallied 3.4% to 28.5%, significantly outperforming the broad market, driven in part by sector-wide momentum around Medicare-related legislation.
The Association Health Plans Act (HR2528) has advanced to the Union Calendar, expanding the addressable market for health insurers in the small group sector by allowing cross-industry associations to offer coverage. The six major health insurer stocks have shown strong positive performance over the past 7 and 30 days, with the legislative catalyst reinforcing bullish momentum in the sector.
HR 4849 permanently eliminates the 400% FPL cap on ACA premium tax credits and establishes zero-premium subsidies for incomes up to 150% FPL, driving 5-7M new exchange enrollees. Real market data shows $MOH (+49.46% 30-day) and $HUM (+46.46% 30-day) leading the sector as pure-play beneficiaries of the deepest subsidy expansion. $UNH (+41.62% 30-day) and $CVS (+19.62% 30-day) also rally but face offsetting factors from PBM margin and OBBBA repeal dynamics.
The Restoring Patient Protections and Affordability Act of 2025 would extend enhanced ACA premium tax credits through 2028, eliminating a 2026 subsidy cliff that threatened exchange enrollment. Managed care and ACA-focused insurers benefit from sustained membership and risk pool stability.
Medicare for All Act (HR3069) would eliminate private health insurance, replacing it with a single-payer federal program. The bill is in early legislative stages (referred to 7 committees, 114 cosponsors, all Democrats). Recent real market data shows private insurers rallied 20-70% over the past 30 days on unrelated factors (likely earnings or regulatory clarity), not legislative risk. A structural existential threat exists for managed care companies if this bill advanced to law — but current legislative probability near zero given Republican House control and early-stage procedural status.